ROC曲线分析血清CA125和CEA鉴别卵巢良恶性肿瘤的临床价值
|
摘要
目的探讨ROC曲线分析血清CA125和CEA鉴别卵巢良恶性肿瘤的临床价值。方法将2015年1月～2018年1月之间收治的50例卵巢囊肿患者(良性组)、50例卵巢恶性肿瘤患者(恶性组)及同时期接受体检的健康女性50例(对照组)作为研究对象;检测三组研究对象血清CA125、CEA的水平,探讨其鉴别良恶性卵巢肿瘤的价值。结果恶性组、良性组及对照组血清CA125分别为(363.95±49.62)IU/ml,(55.64±12.34)IU/ml和(11.21±2.46)IU/ml;血清CEA分别为(12.93±2.49)ng/ml,(3.06±0.59) ng/ml和(2.43±0.46)ng/ml,差异有统计学意义,恶性组显著高于良性组及对照组(P <0.05);对照组CA125、CEA阳性率均为0,良性组联合检测阳性率为16.00%,恶性组为88.00%;以血清CA125为参考,诊断卵巢恶性肿瘤的敏感性为85.3%,特异性为79.6%,ROC曲线下面积为0.86;以血清CEA为参考诊断卵巢恶性肿瘤的敏感性为88.2%,特异性为83.6%,ROC曲线下面积为0.92。结论卵巢恶性肿瘤患者血清CA125和CEA水平显著升高,其可作为鉴别卵巢肿瘤良恶性的血清学标志物。
Objective To explore the clinical value of ROC curve in differentiating benign and malignant ovarian tumors by serum CA125 and CEA. Methods50 cases of ovarian cysts(benign group) and 50 cases of malignant ovarian tumors(malignant group) were treated in our hospital from January 2015 to January2018. Fifty healthy women(control group) who received physical examination in our hospital at the same time were selected as the research objects. The levels of serum CA125 and CEA in the three groups were detected to explore their value in differentiating benign from malignant ovarian tumors. Results The serum CA125 of malignant group, benign group and control group were(363.95±49.62)IU/ml,(55.64±12.34)IU/ml and(11.21 ±2.46)IU/ml, respectively. The serum CEA of malignant group was(12.93±2.49)ng/ml,(3.06±0.59) ng/ml and(2.43±0.46)ng/ml, respectively. The difference was significant. The positive rate of CA125 and CEA of malignant group was significantly higher than that of benign group and control group(P < 0.05). The sex rate was 16.00% in malignant group and 88.00% in malignant group. The sensitivity, specificity and area under ROC curve of serum CA125 were 85.3%, 79.6% and 0.86 respectively. The sensitivity, specificity and area under ROC curve of serum CEA were 88.2%, 83.6% and 0.92 respectively. Conclusion Serum CA125 and CEA levels in patients with ovarian malignant tumors are significantly increased, which can be used as serological markers for differentiating benign and malignant ovarian tumors.
Objective To explore the clinical value of ROC curve in differentiating benign and malignant ovarian tumors by serum CA125 and CEA. Methods50 cases of ovarian cysts(benign group) and 50 cases of malignant ovarian tumors(malignant group) were treated in our hospital from January 2015 to January2018. Fifty healthy women(control group) who received physical examination in our hospital at the same time were selected as the research objects. The levels of serum CA125 and CEA in the three groups were detected to explore their value in differentiating benign from malignant ovarian tumors. Results The serum CA125 of malignant group, benign group and control group were(363.95±49.62)IU/ml,(55.64±12.34)IU/ml and(11.21 ±2.46)IU/ml, respectively. The serum CEA of malignant group was(12.93±2.49)ng/ml,(3.06±0.59) ng/ml and(2.43±0.46)ng/ml, respectively. The difference was significant. The positive rate of CA125 and CEA of malignant group was significantly higher than that of benign group and control group(P < 0.05). The sex rate was 16.00% in malignant group and 88.00% in malignant group. The sensitivity, specificity and area under ROC curve of serum CA125 were 85.3%, 79.6% and 0.86 respectively. The sensitivity, specificity and area under ROC curve of serum CEA were 88.2%, 83.6% and 0.92 respectively. Conclusion Serum CA125 and CEA levels in patients with ovarian malignant tumors are significantly increased, which can be used as serological markers for differentiating benign and malignant ovarian tumors.
引文
[1] Wang F, Zhao X, Tan W, et al. Early identification of recurrence in ovarian cancer:a comparison between the ovarian cancer metastasis index and CA-125 levels[J]. PeerJ, 2018,(6):e5912.
[2] Kristeleit R, Davidenko I, Shirinkin V, et al. A randomised,open-label, phase 2 study of the IDO1 inhibitor epacadostat(INCB024360)versus tamoxifen as therapy for biochemically recurrent(CA-125relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer[J]. Gynecol Oncol, 2017,146(3):484-490.
[3]杨广水. CA125、CA199与CEA联合检测在卵巢癌早期诊断中的价值[J].中国卫生检验杂志, 2013,23(3):699-701.
[4]许强.血清CA125、CA199与CEA联合检测对卵巢癌病情诊断及疗效监测的有效性研究[J].河北医药, 2015,37(15):2263-2265.
[5]高全霞,杨贵岚,张立欣,等. CA19-9、HE4、CEA联合超声造影诊断卵巢癌的价值[J].中国妇幼保健, 2018,33(10):2369-2372.
[6] Eulitt P, Fabian D, Kelly C, et al. Waldenstr?m’s macroglobulinemia masquerading as ovarian cancer with peritoneal carcinomatosis,ascites, and elevated CA-125[J]. Hematol Oncol Stem Cell Ther, 2019,12(1):54-59.
[2] Kristeleit R, Davidenko I, Shirinkin V, et al. A randomised,open-label, phase 2 study of the IDO1 inhibitor epacadostat(INCB024360)versus tamoxifen as therapy for biochemically recurrent(CA-125relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer[J]. Gynecol Oncol, 2017,146(3):484-490.
[3]杨广水. CA125、CA199与CEA联合检测在卵巢癌早期诊断中的价值[J].中国卫生检验杂志, 2013,23(3):699-701.
[4]许强.血清CA125、CA199与CEA联合检测对卵巢癌病情诊断及疗效监测的有效性研究[J].河北医药, 2015,37(15):2263-2265.
[5]高全霞,杨贵岚,张立欣,等. CA19-9、HE4、CEA联合超声造影诊断卵巢癌的价值[J].中国妇幼保健, 2018,33(10):2369-2372.
[6] Eulitt P, Fabian D, Kelly C, et al. Waldenstr?m’s macroglobulinemia masquerading as ovarian cancer with peritoneal carcinomatosis,ascites, and elevated CA-125[J]. Hematol Oncol Stem Cell Ther, 2019,12(1):54-59.